Table 3.
Immune-Related Changes in Hepatic Gene Transcription
| Gene Set | Enrichment Score | FDR q-value |
|---|---|---|
| Regulation of antigen presentation and immune response (M5.0) | -0.63 | 0.003 |
| Enriched in monocytes (II) (M11.0) | -0.56 | 0.003 |
| Myeloid cell enriched receptors and transporters (M4.3) | -0.72 | 0.005 |
| Enriched in antigen presentation (II) (M95.0) | -0.78 | 0.005 |
| TLR and inflammatory signaling (M16) | -0.65 | 0.01 |
| Complement activation (I) (M112.0) | -0.78 | 0.01 |
| Monocyte surface signature (S4) | -0.57 | 0.01 |
| MHC-TLR7-TLR8 cluster (M146) | -0.77 | 0.01 |
| T cell activation and signaling (M5.1) | -0.69 | 0.03 |
| Enriched in NK cells (I) (M7.2) | -0.58 | 0.03 |
| Resting dendritic cell surface signature (S10) | -0.54 | 0.03 |
GSEA using Blood Transcription Module (BTM) gene sets [20]. Notations in parentheses (e.g., “(M5.0)”) show the BTM ID for each gene set. More information for each set is available at https://github.com/shuzhao-li/BTM [20].
FDR-q-value was calculated based on all queried gene sets (e.g., all BTM sets); significant changes in only those sets related to inflammation or immune cell function are shown. A negative enrichment score indicates downregulation of the gene set in tesamorelin treated patients compared to placebo treated patients.
Abbreviations: FDR, false discovery rate; GSEA, Gene Set Enrichment Analysis; NK, natural killer.